These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9009093)

  • 1. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect.
    Bertz H; Burger JA; Kunzmann R; Mertelsmann R; Finke J
    Leukemia; 1997 Feb; 11(2):281-3. PubMed ID: 9009093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma.
    Cabrera R; Díaz-Espada F; Barrios Y; Briz M; Forés R; Barbolla L; Sanjuán I; Regidor C; Peñalver FJ; Fernández MN
    Bone Marrow Transplant; 2000 May; 25(10):1105-8. PubMed ID: 10828874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
    Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF
    J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.
    Zomas A; Stefanoudaki K; Fisfis M; Papadaki T; Mehta J
    Bone Marrow Transplant; 1998 Jun; 21(11):1163-5. PubMed ID: 9645583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-myeloma effect in two cases.
    Verdonck LF; Lokhorst HM; Dekker AW; Nieuwenhuis HK; Petersen EJ
    Lancet; 1996 Mar; 347(9004):800-1. PubMed ID: 8622337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.
    Lokhorst HM; Schattenberg A; Cornelissen JJ; Thomas LL; Verdonck LF
    Blood; 1997 Nov; 90(10):4206-11. PubMed ID: 9354693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families.
    Yado S; Luboshits G; Hazan O; Or R; Firer MA
    J Immunother Cancer; 2019 Nov; 7(1):301. PubMed ID: 31727148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
    Nawa Y; Noguchi T; Kojima K; Hara M
    Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
    van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions.
    Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB
    Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-CSF-mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    J Hematother; 1998 Oct; 7(5):449-56. PubMed ID: 9829319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation.
    Collins RH; Pineiro LA; Nemunaitis JJ; Jain VK; Waxman D; Miller WV; Fay JW
    Transfusion; 1995; 35(11):891-8. PubMed ID: 8604484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
    Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
    Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect.
    Byrne JL; Carter GI; Ellis I; Haynes AP; Russell NH
    Bone Marrow Transplant; 1997 Sep; 20(6):517-20. PubMed ID: 9313888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-myeloma effect: proof of principle.
    Tricot G; Vesole DH; Jagannath S; Hilton J; Munshi N; Barlogie B
    Blood; 1996 Feb; 87(3):1196-8. PubMed ID: 8562947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor leukocyte infusions for multiple myeloma.
    Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
    Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation.
    Keil F; Kalhs P; Chen X; Haas OA; Fritsch G; Chott A; Lechner K; Moser K; Ackermann J; Rabitsch W; Worel N; Mannhalter C; Greinix HT
    Ann Hematol; 1999 Aug; 78(8):376-9. PubMed ID: 10460352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.